All News

ANCA, vasculitis, test

Relapses with Rituximab Maintenance in ANCA-associated Vasculitis

Jack Cush, MD

Real-world, retrospective study of microscopic-polyangiitis (ΜPA) and granulomatosis-with-polyangiitis (GPA) patients shows that rituximab (RTX) maintenance was associated with 25% risk of relapse and that lower relapse rates was seen with RTX plus cyclophosphamide treatment.

Read Article
juvDM1.jpg

CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis

Jack Cush, MD

CARRA has developed consensus treatment plans for the use of biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with refractory, moderately severe juvenile dermatomyositis. Juvenile dermatomyositis is the most common form of idiopathic, inflammatory myositis in childhood, with an estimated incidence of 3.2 per million children per year in the United States.

Read Article
alveolar hemorrhage acute

PEXIVAS: Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis Patients

Jack Cush, MD

A secondary analysis of the PEXIVAS study showed antineutrophil cytoplasmic antibody–associated vasculitis (AAV) patients complicated by diffuse alveolar hemorrhage (DAH) may have improved with plasma exchange and glucocorticoids, the results did not achieve significance. 

Read Article
renal.genes_.jpg

Biologics Prevent AA amyloidosis progression to ESRD

MedPage Today

One of the most serious complications of rheumat0logic and autoimmune diseases can be prevented with biologic drugs, a single-center chart review suggested, and some such products may be more effective than others.

Read Article
cost.price_.biologic.injectable.jpg

Patients with Financial Limits Struggle with Medication Adherence

Jack Cush, MD

Analysis of the National Health Interview Survey shows that nearly 1 in 5 patients with rheumatologic disease in the United States struggled economically, suffering from food insecurity and cost related medication (CRM) nonadherence.

Read Article
Relapses with RTX Maintenance in ANCA-associated Vasculitis A real-world study on ΜPA and GPA patients found that RTX maintenance had a 25% relapse risk, with lower rates when combined with cyclophosphamide treatment. https://t.co/bD6u5JWVqS https://t.co/CSotJt4in1

Links:

Dr. John Cush RheumNow ( View Tweet)
EU study of 1052 systemic sclerosis pts failed to show early immunosuppressive use (vs late) lowered ILD risk. Early Rx (Dz Dur < 3yrs) group (n=547, 52%) more male, diffuse Dz, 60% Rx w/ MTX (1.7% biologics); ILD in 47% after3.6yrs (HR 1.13;0.93–1.38) https://t.co/PtQlgyX0TE https://t.co/R7X3zvPvIg

Links:

Dr. John Cush RheumNow ( View Tweet)
CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis CARRA has developed consensus treatment plans (CTPs) for the use of bDMARDs in patients with refractory, moderately severe juvenile dermatomyositis (JDM). https://t.co/NKikKGxlOY https://t.co/aJk8t5JTip

Links:

Dr. John Cush RheumNow ( View Tweet)
Lead with Lupus (8.2.2024) Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv - leading with lupus because everyone wants to know about lupus! https://t.co/kzoijNGyfd https://t.co/S2llbb0pMO

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA issued draft guidance, which, if implemented, would remove requirement for a switching study for demonstrating biosimilar interchangeability. Citing research showing no additional safety concerns if pts switched from reference biologics to biosimilars https://t.co/MBvI4yxajW https://t.co/sEE654E2rl

Links:

Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/TIdCtJjF21 https://t.co/UE0nGbESDB

Links:

Dr. John Cush RheumNow ( View Tweet)
Guselkumab maintenance dose is 100 mg sc q8wks. GUIDE ph 3b trial treated 297 PSO super responders (PASI <3) w/ q8wk or extended q16wk GUS & demonstrated noninferiority of q16 wk dosing w/ disease control (91.9 vs 92.6%) https://t.co/31DPTmcVD2 https://t.co/qHMsyYCH4J

Links:

Dr. John Cush RheumNow ( View Tweet)
TRUST: 10 Yr Japanese study of tacrolimus in 1355 SLE nephritis pts; half on TAC x 10yrs. TAC use assoc w/ signif reduction corticosteroid use (~16 mg/d @4wks to 7.2 mg/d @ 1Yr(P < 0.001). 9.7% w/ serious AEs. https://t.co/PsfCVZF4tk https://t.co/l3HkTRc4oC

Links:

Dr. John Cush RheumNow ( View Tweet)
FIRST registry of 1424 #RA pts found 732 achieving HAQ-DI <0.5 & 454 w/ pain VAS <4/10. Achieiing LDA in 1st 6mos predicted by seropositivity & JAKi use. Less likely were: older, failin ≥ 2 b/tsDMARDs, hi baseline HAQ& steroid use (not comorbidities) https://t.co/7y0uMV414j https://t.co/6aLPTzf5fm

Links:

Dr. John Cush RheumNow ( View Tweet)
Biologics Prevent AA amyloidosis progression to ESRD The study suggests that biologic drugs can prevent serious complications of rheumatologic and autoimmune diseases, with some products showing greater effectiveness than others. https://t.co/dq5NRrsExv https://t.co/8h1g7LHdCU

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitors Reduce Macular Degeneration Insurance claims data showed that patients with autoimmune disorders who took JAK inhibitors had lower rates of AMD, hinting that the drugs might treat the common eye disease. https://t.co/MuJpbGPqe8 https://t.co/hcp4W3wP8a

Links:

Dr. John Cush RheumNow ( View Tweet)
NEW VIEWPOINT—Arthritis complicating inflammatory bowel disease—the future is now https://t.co/FyojGF6Pvx @DrLauraCoates #GITwitter https://t.co/kMewGTDQTc

Links:

The Lancet Rheumatology TheLancetRheum ( View Tweet)
DBRPCT of Krill oil (4 g/d;KOC) vs PBO in 78 #SLE pts for 24 wks. KOC Rx pts had signif increase in Omega-3 Index 4.3% to 7.17% (4wks) to 8.05% (24wks) w/ no change SLEDAI-2K. But 9pts w/ hi activity (SLEDAI≥9) showed signif Dz activity improvements https://t.co/ODLqqZzGQx https://t.co/tehHk4MhbZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Inspirations About RA-ILD Dr. Jonathan Kay discusses abstracts POS0070, POS0043 and POS0022 presented at the Eular 2024 meeting in Vienna, Austria. https://t.co/sKwr7yMUcX https://t.co/UBTYD5SioS

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE Topic Panel: EULAR 2024 Dr.Jack Cush moderates this topic panel on SLE with Drs. Yuz Yusof and Andrea Fava. https://t.co/nBTiIeGd99 https://t.co/5BK72vbR5V

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×